We are live on ! Find out more
NRSNW icon

NeuroSense Therapeutics Warrant
NRSNW

5 hedge funds and large institutions have $605K invested in NeuroSense Therapeutics Warrant in 2021 Q4 according to their latest regulatory filings, with 5 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
5
Holders Change
+5
Holders Change %
–
% of All Funds
0.08%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
+$379K
2
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
+$134K
3
WAM
Warberg Asset Management
Illinois
+$59.3K
4
UBS Group
UBS Group
Switzerland
+$4K

Top Sellers

No sellers this quarter

NRSNW Hedge Fund Activity: Q4 2021 in Review

5 of the 6,519 institutional investors tracked by Wall St. Rank reported a position in NeuroSense Therapeutics Warrant (NRSNW) for Q4 2021, worth a combined $605K.

Buyers outnumbered sellers: 5 funds opened new NRSNW positions and 0 closed out — a net gain of 5 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Armistice Capital, opening a new position worth an estimated $379K.

  • 5 institutional investors held NeuroSense Therapeutics Warrant (NRSNW) as of Q4 2021, up from 0 in Q3 2021.
  • Funds reported $605K of NeuroSense Therapeutics Warrant stock for Q4 2021.
  • 5 funds opened new NeuroSense Therapeutics Warrant positions in Q4 2021 and 0 closed out, a net change of +5 holders.
  • The largest NeuroSense Therapeutics Warrant buyer in Q4 2021 was Armistice Capital, an estimated $379K added.

Based on aggregated 13F filings for Q4 2021.